Trial Profile
Clinical Study to Evaluate the Efficacy, Safety and Kinetics of Octagam 10% for Replacement Therapy in Primary Immunodeficiency Diseases
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 18 Jul 2017
Price :
$35
*
At a glance
- Drugs Immunoglobulin G (Primary)
- Indications Immunodeficiency disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Octapharma
- 08 Aug 2014 New trial record